bluuebunny/crossref_metadata_2025_split huggingface dataset:
Investigation on vermilion, gingiva, and tooth color of young Uygur and Han populations in Xinjiang, China
Authors: Gao Chengzhi , Adalet Khasim , Liu Haishan , Wang Jing 
Published: February 2010

AbstractThis study examines oral tissue color in Uygur and Han Chinese populations. The color of oral tissues is of great significance in dental field. It remains uncertain whether there is any difference in the color of oral tissues between different nationalities or ethnicities. Little is known about the color of oral tissues in different Chinese populations. The study included 263 Uygur and Han students aged 18–22 years. The color of anterior teeth, vermilion, and attached gingiva in the subjects was measured by spectrophotometry and expressed through the CIELCh system. The t test and ANOVA was used to analyze color difference between groups. Distribution ranges for L (lightness), C (chroma) and h (hue angle) of anterior teeth, vermilion, and attached gingiva in these two ethnicities were obtained. Significant differences in color of oral tissues between Uygur and Han Ethnicities were found out. The Uygur and Han populations have similar spatial distribution ranges for the color of oral tissues, with slight differences that displayed strong regularities, suggesting that the color of oral tissues was associated with race. In addition, there was a trend of decreasing lightness (especially for maxillary anterior teeth), increasing chroma and redder hue from the center of teeth toward the sides in both ethnicities. There were differences in the color of teeth and attached gingiva between sexes in the Uygur and Han populations. The color of the upper vermilion differed significantly from that of the lower vermilion. © 2010 Wiley Periodicals, Inc. Col Res Appl, 2010
Synergistic effect of cinacalcet and active vitamin D in a dialysis patient with secondary hyperparathyroidism
Authors: Karger Christian P. , Schwenger Vedat , Sommerer Claudia , Zeier Martin 
Published: February 2010

AbstractWhile treating a long‐term dialysis patient for secondary hyperparathyroidism (SHPT), indications of a synergistic effect between cinacalcet HCl and active vitamin D were observed. After 2.5 years, high initial cinacalcet doses of 180 mg/day could be significantly reduced to only 30 mg/non‐dialysis day without losing control over the intact parathyroid hormone. Calcium‐phosphorus product improved over time. The combination of cinacalcet and active vitamin D may improve the treatment of SHPT in dialysis patients. Dial. Transplant. © 2010 Wiley Periodicals, Inc.
Fine‐needle aspiration biopsy diagnosis of costal juxtacortical chondrosarcoma presenting as an abdominal mass
Authors: Rosa Marilin , Bajestani Saeed , Davis Cindy , Makary Raafat , Villas Bruce 
Published: February 2010

AbstractThe majority of chondroid tumors arising in the cortex of bone are benign in nature. Juxtacortical chondrosarcoma is a relatively uncommon variant of chondrosarcoma, which by definition, is a malignant cartilaginous tumor that occurs on the surface of bone and measures at least 5 cm.Although the diagnostic value of fine‐needle aspiration biopsy is well established, its role in the diagnosis of soft tissue/bone tumors is still not uniformly accepted. Herein, we describe an interesting and controversial case of costal juxtacortical chondrosarcoma presenting as a large intraabdominal mass in a 52‐year old female patient, which was diagnosed by fine‐needle aspiration biopsy. Diagn. Cytopathol. 2010;38:837–840. © 2010 Wiley‐Liss, Inc.
Circulating concentrations of parathyroid hormone-like peptide in malignancy and in hyperparathyroidism
Authors: Henderson Janet E. , Shustik Chaim , Kremer Richard , Rabbani Shafaat A. , Hendy Geoffrey N. , Goltzman David , Hendy Geoffrey N. , Goltzman David 
Published: February 2010

Abstract
We have examined circulating concentrations of a parathyroid hormone-like peptide (PLP) in patients with malignancies and in patients with hyperparathyroidism. The radioimmunoassay employed reacts with synthetic amino-terminal fragments of PLP but not with parathyroid hormone. Elevated plasma PLP concentrations were observed in 50% of patients with malignancy and hypercalcemia and in 15% of normocalcemic cancer patients, mean values being higher in the former group. Detectable plasma PLP concentrations were found in 2 of 39 control subjects. In 2 patients with breast cancer plasma PLP declined concomitantly with a reduction in tumor burden. Adenocarcinoma of the breast and squamous cell carcinomas were most frequently associated with high plasma PLP levels although a variety of histologic types were represented. The presence of metastases on bone scans did not correlate with either the severity of hypercalcemia or the extent of PLP elevation. Increased concentrations of plasma PLP were also observed in 4 of 20 patients with primary hyperparathyroidism and in 5 of 16 patients with chronic renal failure and secondary hyperparathyroidism. Gel filtration analysis of immunoreactive PLP in plasma from 2 hypercalcemic breast cancer patients revealed heterogeneity, with, in each case, both large (greater than 15 kD) and small (6–) KD) molecular weight amino-terminal moieties. The results document the presence of PLP in the circulation of patients with cancer and are consistent with a pathogenetic role for PLP in the hypercalcemia of malignancy irrespective of whether skeletal metastases have occurred. PLP may also contribute to the skeletal and/or renal manifestations of hyperparathyroid states
Monoclonal antibodies to ros 17/2.8 cells recognize antigens, some of which are restricted to osteoblasts and chondrocytes
Authors: Perry Judith , Gilligan Moira , Green Elaine , Docherty Hilary , Heath David 
Published: February 2010

Abstract
We have raised a panel of 15 monoclonal antibodies (MAbs) recognizing cell surface antigens of the rat osteoblast-like cell line ROS 17/2.8. The MAbs were selected on the basis of preferential binding to ROS 17/2.8 cells compared to ROS 25/1 cells. Immunohistochemical studies of antigen localization on cryostat sections of rat calvaria, long bone, and soft tissues demonstrated that five of these MAbs, UBIM 1, 2, 3, 12, and 17, recognize antigens that are restricted to normal rat osteoblasts and chondrocytes. The antigens appear to be localized to the cell surface of the osteoblast, with no apparent staining of bone matrix in either undecalcified or decalcified sections. In vitro, these MAbs recognize cell surface antigens present on two additional cell lines, ROS 24/1 and Rat 2 cells, and on the adherent cell population cultured from rat long bone marrow. Of these MAbs, three (UBIM 1, 2, and 3) recognize high-molecular-weight antigens of Mr 200,000-225,000. This study has also identified cell surface antigens of ROS 17/2.8 cells that are not expressed by osteoblasts in vivo. MAbs UBIM 9 and 21 bind to marrow cells in long bone sections, to the 7-day-old nonadherent cell population from cultured marrow, and to lymphoid tissue in sections of spleen. Another four MAbs (UBIM 10, 11, 14, and 22) bind to a variety of cells and tissues both in vitro and in vivo. Studies of the interactions of this panel of MAbs with osteogenic tissues and cell lines may have an important impact on the understanding of osteoblast physiology
24- and 26-Homo-1, 25-dihydroxyvitamin D3 Analogs: Potencies on in vitro bone resorption differ from those reported for cell differentiation
Authors: Paulson Susan K. , Perlman Kato , Deluca Hector F. , Stern Paula H. 
Published: February 2010

Abstract
It has been proposed that the stimulatory effects of 1,25-dihydroxyvitamin D on bone resorption may be mediated through actions on differentiation of marrow cells into monocytic osteoclast precursors. In human promyelocytic leukemia cells (HL-60), 24- and 26-homo-1,25-dihydroxyvitamin D3 and their Δ22 analogs and 24,24-dihomo-1,25-dihydroxyvitamin D3 are 10-fold more potent than 1,25-dihydroxyvitamin D3, and Δ22-24,24,24-trihomo-1,25-dihydroxyvitamin D3 is equipotent with 1,25-dihydroxyvitamin D3 in inducing differentiation into the monocytic phenotype. The effect of these 1,25-dihydroxyvitamin D3 analogs on resorption of fetal rat limb bones in vitro was determined in the present study. 1,25-Dihydroxyvitamin D3 was equipotent with 24-homo-1,25-dihydroxyvitamin D3, Δ22-24-homo-1,25-dihydroxyvitamin D3, 26-homo-1,25-dihydroxyvitamin D3, and Δ22-26-homo-1,25-dihydroxyvitamin D3 for in vitro bone resorption, whereas 24,24-dihomo-1,25-dihydroxyvitamin D3 and Δ22-24,24,24-trihomo-1,25-dihydroxyvitamin D3 were inactive. The failure of these analogs to show a higher bone-resorbing activity than 1,25-dihydroxyvitamin D3 provides evidence to suggest that the mechanism of 1,25-dihydroxyvitamin D3-induced bone resorption may not involve stimulation of monocytic cell differentiation
Radioiodinated rat parathyroid hormone-(1-34) binds to its receptor on rat osteosarcoma cells in a manner consistent with two classes of binding sites
Authors: Seitz Patricia K. , Nickols G. Allen , Nickols Maureen A. , McPherson M. Blaire , Cooper Cary W. 
Published: February 2010

Abstract
Binding of 125I-labeled rat (r) PTH-(1-34) to ROS 17/2.8 osteoblastic bone cells and to membranes from these cells was examined. Competitive binding inhibition experiments were performed using unlabeled rPTH-(1-34) with particular emphasis on concentrations of peptide below 1 nM. In intact cells, binding of labeled rPTH-(l-34) was highly specific, and inhibition of binding by unlabeled ligand suggested the presence of two classes of binding sites, one with high affinity and low capacity (KD = 40 pM, approximately 20% of total binding sites) and the other with lower affinity and high capacity (KD = 2 nM, approximately 80% of the sites). Membranes prepared from ROS cells also exhibited a pattern of binding from competitive inhibition curves consistent with two distinct binding sites (KD = 30 pM and 6 nM). In intact ROS cells, cellular cAMP levels increased over the range of 10−11-10−9 M rPTH-(l-34) with an ED50 intermediate between the two KD values (0.25 nM). These data suggest that osteoblastic bone cells possess two distinct classes of membrane receptors for PTH. Since the KD of the higher affinity site more closely approximates circulating concentrations of PTH, binding to this site may have physiologic relevance.
Human lactation: Forearm trabecular bone loss, increased bone turnover, and renal conservation of calcium and inorganic phosphate with recovery of bone mass following weaning
Authors: DR. Kent G. Neil , Price Roger I. , Gutteridge Donald H. , Allen Janet R. , Barnes Marion P. , Hickling Caroline J. , Retallack Robert W. , Wilson Scott G. , Devlin Rowena D. , Price Roger I. , Smith Margaret , Bhagat Chotoo I. , Davies Charmian , St. Johns Andrew 
Published: February 2010

Abstract
The calcium (Ca) metabolism of established human lactation was studied in 40 adult women (mean age 32.4 years) who had been breast-feeding for 6 months (Lac) and in 40 age-matched controls (Con) using fasting urine and blood biochemistry and forearm single-photon bone mineral densitometry (BMD). Serial studies were performed up to 6 months after weaning in Lac women and repeated once in Con women. During lactation the significant findings were (1) a selective reduction (7.1%, P &lt; 0.03) in BMD at the ultradistal site containing 60% trabecular bone, but not at two more proximal, chiefly cortical bone sites; (2) increased bone turnover affecting bone resorption [fasting hydroxyproline excretion, Lac 2.22 + 0.12 μmol/liter GF (mean + SEM), Con 1.19 + 0.04, P &lt; 0.001] and affecting bone formation (plasma alkaline phosphatase, Lac 81.9 + 2.5 IU/liter, Con 53.5 + 2.7, P &lt; 0.001, and serum osteocalcin, Lac 14.0 + 0.7 μg/liter, Con 7.3 + 0.4, P &lt; 0.001); and (3) renal conservation in the fasting state of both Ca and inorganic phosphate (Pi) with a resultant moderate increase in plasma Pi but not in plasma Ca (total or ionized). There were no differences between the groups in serum parathyroid hormone (PTH, intact and midmolecule assays), 25-hydroxy- and 1,25-dihydroxyvitamin D, nephrogenous cyclic AMP production, or plasma creatinine. In 25 of these Lac women restudied at one or more of the times 2, 4, or 6 months after weaning, the findings were (1) an early (2 months) normalization of bone resorption and renal Pi handling with continuing increased bone formation and renal Ca conservation, associated with the onset of increased intact PTH levels; and (2) a recovery, within 4-6 months in ultradistal BMD associated with normalization of bone formation but with persisting renal Ca conservation and elevated intact PTH levels. We conclude that in established adult human lactation there is increased bone turnover with an accompanying loss of trabecular bone, despite renal conservation of Ca and Pi. After weaning, the deficit in trabecular bone is made up during a period of imbalance between a normal bone resorption rate and an elevated bone formation rate. The moderately elevated PTH after weaning may play a role in the recovery of bone mass by maintaining renal Ca conservation and by an anabolic action on bone.
Normal left ventricular performance in children with x-linked hypophosphatemic rickets: A doppler echocardiography study
Authors: Vered Iris , Dr. Whyte Michael P. , Vered Zvi , Perez Julio E. , Jaffe Allan S. 
Published: February 2010

Abstract
To determine if chronic hypophosphatemia causes myocardial dysfunction, we explored one model for this metabolic derangement by prospectively investigating 11 patients (aged 5-18 years) with X-linked hypophosphatemic rickets (XLH) by M-mode, two-dimensional, and Doppler echocardiography. Inorganic phosphate and calcitriol (1,25-dihydroxyvitamin D3) treatment was withheld 72 h prior to study.
None of the patients had cardiovascular symptoms. Fasting serum inorganic phosphate concentrations were subnormal in all: 2.6 + 0.5 mg/dl (SD). Serum total and ionized calcium, magnesium, sodium, potassium, and creatine kinase myocardial fraction (CK-MB) levels were unremarkable. Electrocardiograms revealed early repolarization abnormalities in 3 of the 11 patients: 1 had significant QT prolongation (corrected for heart rate), and 2 had T wave abnormalities. Exaggerated U waves occurred in 4 subjects. Resting echocardiograms were normal in 9 patients. In 1 subject there was mitral valve prolapse, and 1 patient possibly had an atrial septal defect (these findings were considered unrelated to hypophosphatemia). All M-mode measurements were normal. The two-dimensionally derived end-diastolic and end-systolic left ventricular volumes were 60.3 + 18.0 and 20.5 + 6.9 ml, respectively. Left ventricular ejection fraction was 66.1 + 4.7%, and the cardiac index by Doppler study was 4.1 + 0.8 liters/min per m2 (both values were within normal limits).
Although the precise pathogenesis of XLH is unknown and our findings suggest that some electrocardiographic abnormalities may be common in this disorder, we found no evidence for left ventricular dysfunction in this human model of clinically significant long-standing hypophosphatemia.
Treatment of paget's disease of bone with aminohydroxybutylidene bisphosphonate
Authors: O'Doherty Declan P. , Bickerstaff Derek R. , Mccloskey Eugene V. , Hamdy Neveen A. T. , Beneton Monique N. C. , Mian M. , Dr. Kanis John A. , Harris Steven 
Published: February 2010

Abstract
This study examined the effects of aminohydroxybutylidene bisphosphonate in 30 patients with Paget's disease of bone, administered as an intravenous infusion for 5 consecutive days. Treatment (5 mg IV daily) induced marked suppression of biochemical indices of disease activity. Urinary excretion of hydroxyproline fell to 50% of pretreatment values within 2 weeks and was followed by a similar, but later, decline in the serum activity of alkaline phosphatase. Disease activity remained suppressed throughout the 6 months of observation, and only 1 patient showed biochemical signs of an early relapse. Symptomatic improvement was noted in 27 of the 30 patients. Bone biopsies, undertaken in 10 patients, indicated no adverse effects on mineralization. Transient falls were noted in the total white cell count, particularly the lymphocyte and neutrophi1 fractions, and were associated with short-lived fever in 3 patients. We conclude that short courses of intravenous AHButBP provide a promising treatment for active Paget's disease of bone.
Chemical and physical properties of the extracellular matrix are required for the actin ring formation in osteoclasts
Authors: Nakamura Ichiro , Takahashi Naoyuki , Sasaki Takahisa , Jimi Eijiro , Kurokawa Takahide , Suda Tatsuo 
Published: February 2010

Abstract
To examine the effect of extracellular matrix on osteoclast polarization, we focused on the actin organization in osteoclasts, using murine osteoclast-like multinucleated cells (OCLs) formed in cocultures of osteoblastic cells and bone marrow cells. When OCLs were cultured on either a plastic plate, calcified dentine, or calcium phosphate thin films in the presence of fetal bovine serum (FBS), they similarly formed ringed structures of F-actin dots (actin rings). However, OCLs placed on demineralized dentine or type I collagen gel matrix (collagen gel) failed to form actin rings. In the absence of FBS, actin ring formation in OCLs was induced on plastic plates coated with vitronectin, fibronectin, or type I collagen, but not on those coated with laminin, poly-L-lysine, or bovine serum albumin. Actin ring formation appeared to depend on integrins, since the GRGDS, but not the GRGES, peptide inhibited it in a dose-dependent manner. Moreover, immunoelectron microscopic examination revealed that vacuolar proton ATPase (V-ATPase) was localized along the apical membrane in much higher densities than the basolateral membrane in OCLs placed on plastic coverslips. In OCLs placed on collagen gel, however, V-ATPase was found to be distributed throughout the cytoplasm without polarity. These results suggest that actin ring formation in osteoclasts was dependent on matrix substrates, matrix proteins and integrins, and was closely related to osteoclast function.
Changes in parathyroid hormone receptor binding affinity during egg laying: Implications for calcium homeostasis in chicken
Authors: Yasuoka Tadashi , Kawashima Mitsuo , Takahashi Tetsuya , Iwata Atsushi , Oka Nobumitsu , Tanaka Katuhide 
Published: February 2010

Abstract
Parathyroid hormone (PTH) receptor bindings were examined in the membrane fraction of the calvaria and the kidney of the hen by the use of [125I]PTH-related protein (PTHrP) binding assays. The binding specificity, reversibility, and saturation of the receptor were demonstrated. The equilibrium dissociation constant (Kd) and the maximum binding capacity (Bmax) were obtained by Scatchard analyses. In both calvaria and kidney, Kd and Bmax values decreased at 3 h before oviposition in egg-laying hens, but not in nonlaying hens. Administration of 17β-estradiol or progesterone in vivo caused a decrease in the Kd and Bmax values. Ionized calcium concentrations in the blood plasma showed a decrease at 13 h before oviposition. The results suggest that the PTH receptor binding in the calvaria and the kidney is affected by ovarian steroid hormones and may play a role in maintaining the calcium homeostasis in the egg-laying hen.
Systemically and locally administered growth hormone stimulates bone healing in combination with osteopromotive membranes: An experimental study in rats
Authors: Hedner Ewa , Linde Anders , Nilsson Anders 
Published: February 2010

Abstract
Growth hormone (GH) is known to be of a major importance for longitudinal bone growth, but its local effects on osteogenesis and, thus, regeneration of bone defects are less known. The aim of this investigation was to study whether GH, systemically or locally administered, has any stimulatory effects on local osteogenesis, utilizing standardized, membrane-covered, transosseous defects (5 mm diameter) in mandibles of adult albino rats. The study also addressed the question of whether GH might be a feasible option to further promote bone regeneration and neogenesis in conjunction with expanded polytetrafluoroethylene (e-PTFE) “osteopromotive” membranes (GORE-TEX®). Human GH (hGH; 0.2, 2, 20, 200 μg/day), bovine GH (bGH; 200 μg/day), prolactin (200 μg/day) or saline was administered systemically by means of mini-osmotic pumps, implanted subcutaneously at the back of the animal. Healing was analyzed after 2, 3, and 4 weeks. Healing was also studied after local administration, just outside the defects, of hGH (0.2, 2, 20 μg/day) via catheters connected to mini-osmotic pumps during 4 weeks. Human GH and bGH stimulated local bone formation compared to saline and prolactin. Bone formation was significantly promoted by systemically administrated hGH, after 3 weeks and at 2 μg/day or higher concentrations. Enhanced bone formation was also found after 4 weeks in animals given 0.2, 2 and 20 μg/day of hGH locally, compared to local administration of saline. The results show that GH exerts a direct, nonliver mediated effect on bone tissue. Moreover, the study suggests that hGH may be used to stimulate bone healing and formation in conjunction with osteopromotive membranes.
Induction chemotherapy in the management of head and neck cancer
Authors: Fury Matthew G. , Shah Jatin P. 
Published: February 2010

AbstractThe strategy of induction chemotherapy prior to planned definitive local therapy for head and neck squamous cell carcinoma has been studied for over 30 years, and appears to have a role in select clinical situations. Here we review landmark studies regarding induction chemotherapy, both in the pre‐taxane era and in the current taxane era, and we address some of the unresolved questions regarding the role of induction chemotherapy in head and neck cancer. J. Surg. Oncol. 2010; 101:292–298. © 2010 Wiley‐Liss, Inc.
Neoadjuvant strategies for the treatment of locally advanced esophageal cancer
Authors: Hyngstrom John R. , Posner Mitchell C. 
Published: February 2010

AbstractPatients with locally advanced esophageal carcinoma have consistently poor survival following surgery with associated high systemic and local‐regional failure rates. Neoadjuvant therapeutic strategies have been employed in an attempt to improve outcome with variable success. Randomized trials of either neoadjuvant chemotherapy or chemoradiotherapy have shown conflicting results regarding survival and local‐regional control. Future efforts should focus on identifying novel agents and targets to improve therapeutic efficacy. J. Surg. Oncol. 2010; 101:299–304. © 2010 Wiley‐Liss, Inc.
Neoadjuvant treatment of soft‐tissue sarcoma: A multimodality approach
Authors: Reynoso David , Subbiah Vivek , Trent Jonathan C. , Guadagnolo B. Ashleigh , Lazar Alexander J. , Benjamin Robert , Pollock Raphael E. , Ludwig Joseph A. 
Published: February 2010

AbstractUnlike epithelial cancers that are both more homogeneous and easily categorized by their respective tissues of origin (e.g., breast or lung cancer), sarcomas represent a diverse class of molecularly distinct bone and soft‐tissue mesenchymal neoplasms of more than 50 subtypes. This diversity, as well as the relative rarity of sarcomas as a whole, has presented challenges in conducting prospective randomized clinical trials to assess the value of neoadjuvant chemotherapy for any given subtype. Most clinical trials and meta‐analyses have neglected the phenotypic and molecular heterogeneity differentiating one sarcoma subtype from another in favor of a simplified grouping that ensures timely trial completion. As the success of treating gastrointestinal stromal tumors (GISTs) with imatinib demonstrates, a decision to provide neoadjuvant chemotherapy must take into consideration both the subtype being treated and the effect such treatment would be expected to exert upon that subtype. J. Surg. Oncol. 2010; 101:327–333. © 2010 Wiley‐Liss, Inc.